Preview

Russian Journal of Pediatric Hematology and Oncology

Advanced search

Actual issues of production and use of immunological drugs from human blood plasma in modern medicine (based on the materials of the First Intercontinental Academy on Immunology and Congenital Angioedema)

https://doi.org/10.17650/2311-1267-2017-4-4-78-84

Abstract

One of the fundamentals of high-tech therapy in immunology, neurology, hematology-oncology and other areas of medicine is the use of immunological drugs isolated from the blood plasma of healthy donors. It is known that the indications and the routes of drug administration (in particular, immunoglobulins) are based on  numerous studies of its efficiency in various diseases, traditionally  the attention of physicians is precisely focused on it. However, in the  21st century, the safety and convenience for the patient and medical personnel are no less important. The article presents a modern  manufacturing enterprise of blood plasma preparations and data on  its application in the field of immunology, hematology-oncology and  neurology according to the First Intercontinental Academy on Immunology and Congenital Angioedema.

About the Author

K. I. Kirgizov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
1 Samory Mashela St., Moscow, 117997, Russia


References

1. Киргизов К.И., Скоробогатова Е.В. Внутривенные иммуноглобулины: применение современных физиологичных растворов способно улучшить результаты терапии. Российский журнал детской гематологии и онкологии 2015;2(2):77–83. [Kirgizov K.I., Skorobogatova E.V. Intravenous immunoglobulins: application of modern physiological solution is able to improve results of the therapy. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2015;2(2):77–83. (In Russ.)].

2. Durandy A., Kaveri S.V., Kuijpers T.W. et al. Intravenous immunoglobulins--understanding properties and mechanisms. Clin Exp Immunol 2009;158 Suppl 1:2–13. doi: 10.1111/j.1365-2249.2009.04022.x.

3. Dantal J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol 2013;38(4):275–84. doi: 10.1159/000354893.

4. Lozano-Blasco J., Martín-Mateos M.A., Alsina L. et al. A 10 % liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG. Allergol Immunopathol (Madr) 2014;42(2):136–41. doi: 10.1016/j.aller.2012.10.006


Review

For citations:


Kirgizov K.I. Actual issues of production and use of immunological drugs from human blood plasma in modern medicine (based on the materials of the First Intercontinental Academy on Immunology and Congenital Angioedema). Russian Journal of Pediatric Hematology and Oncology. 2017;4(4):78-84. (In Russ.) https://doi.org/10.17650/2311-1267-2017-4-4-78-84

Views: 560


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2311-1267 (Print)
ISSN 2413-5496 (Online)
X